Current Understanding of Pneumocystis Immunology

Overview

Journal Future Microbiol

Specialties Infectious Diseases
Microbiology

Date 2009 Dec 22

PMID 20020829

Citations 40

Authors

Michelle N Kelly

Judd E Shellito

Affiliations

Soon will be listed here.

Abstract

Pneumocystis jirovecii is the opportunistic fungal organism that causes Pneumocystis pneumonia (PCP) in humans. Similar to other opportunistic pathogens, Pneumocystis causes disease in individuals who are immunocompromised, particularly those infected with HIV. PCP remains the most common opportunistic infection in patients with AIDS. Incidence has decreased greatly with the advent of HAART. However, an increase in the non-HIV immunocompromised population, noncompliance with current treatments, emergence of drug-resistant strains and rise in HIV(+) cases in developing countries makes Pneumocystis a pathogen of continued interest and a public health threat. A great deal of research interest has addressed therapeutic interventions to boost waning immunity in the host to prevent or treat PCP. This article focuses on research conducted during the previous 5 years regarding the host immune response to Pneumocystis, including innate, cell-mediated and humoral immunity, and associated immunotherapies tested against PCP.

Citing Articles

Risk of Pneumonia in Patients With HIV in Taiwan: Evidence from a Cross-sectional Study.

Wang J, Huang K, Tai C, Gau S, Tsai T, Wu C In Vivo. 2025; 39(2):1054-1066.

PMID: 40010982 PMC: 11884483. DOI: 10.21873/invivo.13910.

Mucosal T-cell responses to chronic viral infections: Implications for vaccine design.

Al-Talib M, Dimonte S, Humphreys I Cell Mol Immunol. 2024; 21(9):982-998.

PMID: 38459243 PMC: 11364786. DOI: 10.1038/s41423-024-01140-2.

Embigin Is Highly Expressed on CD4+ and CD8+ T Cells but Is Dispensable for Several T Cell Effector Responses.

Yang H, Iwanaga N, Katz A, Ridley A, Miller H, Allen M Immunohorizons. 2024; 8(3):242-253.

PMID: 38446446 PMC: 10985056. DOI: 10.4049/immunohorizons.2300083.

Dynamics of host immune responses and a potential function of Trem2 interstitial macrophages in Pneumocystis pneumonia.

Yang H, Sun H, Li K, Shao M, Zhai K, Tong Z Respir Res. 2024; 25(1):72.

PMID: 38317180 PMC: 10845524. DOI: 10.1186/s12931-024-02709-1.

Pneumocystis jirovecii pneumonia after CD4+ T-cell recovery subsequent to CD19-targeted chimeric antigen receptor T-cell therapy: A case report and brief review of literature.

Kawata K, Shima H, Shinjoh M, Yamazaki F, Kurosawa T, Yaginuma M Cancer Rep (Hoboken). 2023; 6(10):e1885.

PMID: 37563749 PMC: 10598253. DOI: 10.1002/cnr2.1885.

References

Zelante T, De Luca A, DAngelo C, Moretti S, Romani L . IL-17/Th17 in anti-fungal immunity: what's new?. Eur J Immunol. 2009; 39(3):645-8. DOI: 10.1002/eji.200839102. View

Rodriguez M, Fishman J . Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev. 2004; 17(4):770-82, table of contents. PMC: 523555. DOI: 10.1128/CMR.17.4.770-782.2004. View

Wilson C, Lewis D . Basis and implications of selectively diminished cytokine production in neonatal susceptibility to infection. Rev Infect Dis. 1990; 12 Suppl 4:S410-20. DOI: 10.1093/clinids/12.supplement_4.s410. View

Vuk-Pavlovic Z, Mo E, Icenhour C, Standing J, Fisher J, Limper A . Surfactant protein D enhances Pneumocystis infection in immune-suppressed mice. Am J Physiol Lung Cell Mol Physiol. 2005; 290(3):L442-9. DOI: 10.1152/ajplung.00112.2005. View

Stringer J, Beard C, Miller R, Wakefield A . A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002; 8(9):891-6. PMC: 2732539. DOI: 10.3201/eid0809.020096. View

Garvy B, Wiley J, Gigliotti F, Harmsen A . Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun. 1997; 65(12):5052-6. PMC: 175728. DOI: 10.1128/iai.65.12.5052-5056.1997. View

Leigh T, Kangro H, Gazzard B, Jeffries D, Collins J . DNA amplification by the polymerase chain reaction to detect sub-clinical Pneumocystis carinii colonization in HIV-positive and HIV-negative male homosexuals with and without respiratory symptoms. Respir Med. 1993; 87(7):525-9. DOI: 10.1016/0954-6111(93)90008-n. View

Wright T, Gigliotti F, Finkelstein J, McBride J, An C, Harmsen A . Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest. 1999; 104(9):1307-17. PMC: 409816. DOI: 10.1172/JCI6688. View

Jones T . The effect of granulocyte-macrophage colony stimulating factor (rGM-CSF) on macrophage function in microbial disease. Med Oncol. 1996; 13(3):141-7. PMC: 7102098. DOI: 10.1007/BF02990842. View

10.

Linke M, Ashbaugh A, Koch J, Tanaka R, Walzer P . Efficient resolution of Pneumocystis murina infection in surfactant protein A-deficient mice following withdrawal of corticosteroid-induced immunosuppression. J Med Microbiol. 2006; 55(Pt 2):143-147. DOI: 10.1099/jmm.0.46190-0. View

11.

Levy J . The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 2001; 22(6):312-6. DOI: 10.1016/s1471-4906(01)01925-1. View

12.

Koziel H, Phelps D, Fishman J, Armstrong M, Richards F, Rose R . Surfactant protein-A reduces binding and phagocytosis of pneumocystis carinii by human alveolar macrophages in vitro. Am J Respir Cell Mol Biol. 1998; 18(6):834-43. DOI: 10.1165/ajrcmb.18.6.3059. View

13.

Rosenzweig S, Holland S . Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol. 2004; 113(4):620-6. DOI: 10.1016/j.jaci.2004.02.001. View

14.

Griese M . Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J. 1999; 13(6):1455-76. DOI: 10.1183/09031936.99.13614779. View

15.

Ding K, Shibui A, Wang Y, Takamoto M, Matsuguchi T, Sugane K . Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine Pneumocystis pneumonia. Microbes Infect. 2005; 7(2):195-203. DOI: 10.1016/j.micinf.2004.10.010. View

16.

Atochina E, Beers M, Scanlon S, Preston A, Beck J . P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am J Physiol Lung Cell Mol Physiol. 2000; 278(3):L599-609. DOI: 10.1152/ajplung.2000.278.3.L599. View

17.

De Stefano J, Cushion M, Puvanesarajah V, Walzer P . Analysis of Pneumocystis carinii cyst wall. II. Sugar composition. J Protozool. 1990; 37(5):436-41. DOI: 10.1111/j.1550-7408.1990.tb01168.x. View

18.

Rudner X, Happel K, Young E, Shellito J . Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun. 2007; 75(6):3055-61. PMC: 1932856. DOI: 10.1128/IAI.01329-06. View

19.

Lund F, Schuer K, Hollifield M, Randall T, Garvy B . Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody. J Immunol. 2003; 171(3):1423-30. DOI: 10.4049/jimmunol.171.3.1423. View

20.

McAllister F, Mc Allister F, Steele C, Zheng M, Young E, Shellito J . T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol. 2004; 172(2):1132-8. DOI: 10.4049/jimmunol.172.2.1132. View